BSX Stock Risk & Deep Value Analysis
Boston Scientific Corp
Healthcare • Medical Devices
DVR Score
out of 10
What You Need to Know About BSX Stock
We analyzed Boston Scientific Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran BSX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
Get notified when BSX moves
Same alert types as Telegram — presets or custom thresholds in your 🔔 feed.
📈BSX Performance Overview3yr weekly
Unlock BSX Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
BSX Risk Analysis & Red Flags
What Could Go Wrong
The proposed Penumbra acquisition, while strategic, carries integration risks and could lead to higher-than-expected costs or slower-than-expected synergies, potentially impacting profitability and management's focus over the next 12-24 months. Further, a broader economic downturn could impact hospital capital expenditures and elective procedures, slowing core revenue growth.
Risk Matrix
Overall
Moderate
Financial
Low
Market
Low
Competitive
Medium
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Slight revenue miss in Q1 2026, though organic growth remains strong.
- ⚠
Limited specific balance sheet and cash flow details in provided real-time intelligence, requiring reliance on general knowledge for an established large-cap.
- ⚠
No clear analyst consensus or institutional ownership percentage in provided data.
Upcoming Risk Events
- 📅
Negative results from clinical trials for new products
- 📅
Delays or failure in integrating acquired companies like Penumbra
- 📅
Increased competitive pressure from major players
When to Reconsider
- 🚪
Sustained organic revenue growth below 5% for two consecutive quarters.
- 🚪
Operating margins decline consistently below 25% due to integration issues or pricing pressure.
- 🚪
Significant negative news regarding product recalls or major regulatory setbacks.
Unlock BSX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Boston Scientific Corp (BSX) Do?
Market Cap
$79.73B
Sector
Healthcare
Industry
Medical Devices
Employees
53,000
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Visit Boston Scientific Corp WebsiteInvestment Thesis
Boston Scientific represents a stable, growing investment in the medical device sector, benefiting from an aging population and increasing demand for minimally invasive procedures. Its strategic acquisition of Penumbra and consistent organic growth in key segments position it for continued moderate capital appreciation and market leadership, though not 10x exponential growth.
Is BSX Stock Undervalued?
Unlock the full AI analysis for BSX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
BSX Price Targets & Strategy
12-Month Target
$68.20
Bull Case
$75.00
Bear Case
$48.00
Valuation Basis
Based on 22x forward P/E applied to estimated FY2026 Adjusted EPS of $3.10 (blended from Q1 run rate and historical trends) = $68.20
Entry Strategy
Consider dollar-cost averaging in the $50-$54 range, near recent support and current levels, or on any dips towards $48-$50.
Exit Strategy
Take profit at $68-$72; implement a stop-loss order at $48.00 (below 52-week lows if applicable to market sentiment, but here based on a 12% downside from current price).
Portfolio Allocation
3% for moderate risk tolerance
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is BSX Financially Healthy?
Valuation
P/E Ratio
22.36
Forward P/E
17.57
PEG Ratio
0.94
Profitability
Gross Margin
69.11%
Operating Margin
18.40%
Net Margin
17.29%
Return on Equity
12.57%
Revenue Growth
17.44%
EPS
$2.38
Balance Sheet
Current Ratio
1.62
Quick Ratio
1.02
Debt/Equity
0.47
Cash Flow
Free Cash Flow
$3.66B
Other
Beta (Volatility)
0.62
Does BSX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable to Expanding
Moat Sources
3 Identified
Boston Scientific's moat is durable due to the high regulatory barriers and significant R&D investment required in the medical device industry, creating strong brand loyalty and established relationships with healthcare providers. Its extensive patent portfolio protects its innovations.
Moat Erosion Risks
- •Disruptive technological innovations from smaller, agile competitors.
- •Increased pricing pressure from healthcare systems or insurance providers.
- •Changes in regulatory approval processes or reimbursement policies.
BSX Competitive Moat Analysis
Sign up to see competitive advantages
BSX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral, as a large-cap healthcare company, it generally doesn't attract significant retail social media hype, typically followed for stability.
Institutional Sentiment
Neutral to Positive, given consistent performance and strategic M&A, though specific upgrades/downgrades were unavailable in research.
Insider Activity (Form 4)
May 11, 2026: Director granted 3,800 restricted shares. May 4, 2026: Ownership change reported (details unspecified). No significant CEO/CFO open market buys/sells flagged.
Options Flow
Normal options activity; no specific data provided to indicate unusual institutional positioning.
Earnings Intelligence
Next Earnings
2026-07-29 (estimated)
Surprise Probability
Medium (Q1 EPS beat, but revenue slightly missed estimates, indicating mixed predictability)
Historical Earnings Pattern
Historically, BSX tends to show moderate price movements following earnings, often reacting positively to EPS beats and strong guidance, but can be sensitive to revenue misses or cautious outlooks.
Key Metrics to Watch
Competitive Position
Top Competitor
Medtronic (MDT)
Market Share Trend
Stable to Gaining, particularly in areas like structural heart and peripheral interventions, bolstered by strategic acquisitions and R&D.
Valuation vs Peers
Likely trading at a comparable or slight premium to peers on P/E, given consistent organic growth and strategic acquisitions, but specific data was not provided in the research context.
Competitive Advantages
- •Extensive product portfolio across multiple high-growth medical specialties.
- •Strong global distribution and sales network.
- •Robust R&D pipeline and intellectual property in key therapeutic areas.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive BSX Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings (estimated July 29, 2026)
- •Completion of Penumbra acquisition and integration updates
- •Pipeline product advancements or regulatory approvals
Medium-Term (6-18 months)
- •Synergies and market share expansion from Penumbra acquisition
- •Geographic expansion into emerging markets
- •Continued growth in Cardiovascular and MedSurg segments
Long-Term (18+ months)
- •Aging global population driving demand for medical devices
- •Technological advancements in minimally invasive procedures
- •Diversification into new therapeutic areas
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for BSX?
- ✓
Sustained organic revenue growth above 9-10% consistently.
- ✓
Successful integration and accretive impact of the Penumbra acquisition.
- ✓
Expansion of adjusted operating margins towards 30%.
Bull Case Analysis
Sign up free to see the bull case
Competing with BSX
See how Boston Scientific Corp compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Boston Scientific Corp BSX | $79.7B | 0.1 | 22.4 | $20.8B | 17.3% | 17.4% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Boston Scientific Corp Makes Money
Boston Scientific designs, develops, manufactures, and markets a broad range of medical devices used in various interventional medical specialties. The company generates revenue primarily by selling its medical products and technologies to hospitals, clinics, and other healthcare providers globally. Its business model thrives on innovation, regulatory approvals, and strong relationships with medical professionals to address a wide array of patient needs.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Boston Scientific Corp (BSX)?
As of May 11, 2026, Boston Scientific Corp has a DVR Score of 0.1 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Boston Scientific Corp?
Boston Scientific Corp's market capitalization is approximately $79.7B. The company operates in the Healthcare sector within the Medical Devices industry.
What ticker symbol does Boston Scientific Corp use?
BSX is the ticker symbol for Boston Scientific Corp. The company trades on the NYQ.
What is the risk level for BSX stock?
Our analysis rates Boston Scientific Corp's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of BSX?
Boston Scientific Corp currently has a price-to-earnings (P/E) ratio of 22.4. This is in line with broader market averages.
Is Boston Scientific Corp's revenue growing?
Boston Scientific Corp has reported revenue growth of 17.4%. The company is showing strong top-line momentum.
Is BSX stock profitable?
Boston Scientific Corp has a profit margin of 17.3%. The company is profitable but margins are modest.
How often is the BSX DVR analysis updated?
Our AI-powered analysis of Boston Scientific Corp is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 11, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for BSX (Boston Scientific Corp) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.